Prior to that Hinchen was the president and chief operating officer of JHP since the formation of the company in 2007.
Hinchen said JHP has a wonderful opportunity over the coming years to actively redefine the generic injectable competitive landscape in the USA.
"Peter remains a valued architect of our business development efforts and how we progress the company through future growth," Hinchen said.